AcelRx Pharmaceuticals Inc. [ACRX] moved up 9.76: Why It’s Important

AcelRx Pharmaceuticals Inc. [NASDAQ: ACRX] closed the trading session at $1.35 on 05/26/21. The day’s price range saw the stock hit a low of $1.24, while the highest price level was $1.36. The company report on May 26, 2021 that Presentation on the Use of DSUVIA® for Plastic Surgery Procedures Selected for “Best Papers” Session at the California Society of Plastic Surgeons Annual Meeting.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced an upcoming podium presentation on DSUVIA (sufentanil sublingual tablet 30 mcg) which was selected for the Best Papers of the Regional Societies session at the California Society of Plastic Surgeons 71st Annual Meeting in Monterey CA.

Hisham Seify, MD, PhD, FACS will present data on the efficacy and safety of DSUVIA for use in general anesthesia plastic surgery cases, and “awake” cosmetic procedures performed at the Newport Plastic and Reconstructive Surgery’s center. The data is from an investigator-initiated trial supported by AcelRx. Dr. Seify is a board-certified plastic surgeon and the past-president of the Orange County Society of Plastic Surgeons.

The stocks have a year to date performance of 8.87 percent and weekly performance of 11.57 percent. The stock has been moved at -7.53 percent over the last six months. The stock has performed 3.85 percent around the most recent 30 days and changed -30.41 percent over the most recent 3-months.

If compared to the average trading volume of 2.33M shares, ACRX reached to a volume of 2057166 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about AcelRx Pharmaceuticals Inc. [ACRX]:

Credit Suisse have made an estimate for AcelRx Pharmaceuticals Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on July 20, 2020. While these analysts kept the previous recommendation, Credit Suisse dropped their target price from $7 to $2. The new note on the price target was released on November 11, 2019, representing the official price target for AcelRx Pharmaceuticals Inc. stock.

The Average True Range (ATR) for AcelRx Pharmaceuticals Inc. is set at 0.11, with the Price to Sales ratio for ACRX stock in the period of the last 12 months amounting to 29.47.

ACRX stock trade performance evaluation

AcelRx Pharmaceuticals Inc. [ACRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.57. With this latest performance, ACRX shares gained by 3.85% in over the last four-week period, additionally sinking by -7.53% over the last 6 months – not to mention a drop of -13.18% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRX stock in for the last two-week period is set at 55.70, with the RSI for the last a single of trading hit 62.18, and the three-weeks RSI is set at 51.12 for AcelRx Pharmaceuticals Inc. [ACRX]. The present Moving Average for the last 50 days of trading for this stock 1.3714, while it was recorded at 1.2840 for the last single week of trading, and 1.5804 for the last 200 days.

AcelRx Pharmaceuticals Inc. [ACRX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and AcelRx Pharmaceuticals Inc. [ACRX] shares currently have an operating margin of -747.10 and a Gross Margin at -11.37. AcelRx Pharmaceuticals Inc.’s Net Margin is presently recorded at -745.55.

Return on Total Capital for ACRX is now -58.35, given the latest momentum, and Return on Invested Capital for the company is -65.77. Additionally, ACRX Total Debt to Total Capital is recorded at 195.59, with Total Debt to Total Assets ending up at 172.06.

Reflecting on the efficiency of the workforce at the company, AcelRx Pharmaceuticals Inc. [ACRX] managed to generate an average of -$747,759 per employee. Receivables Turnover for the company is 8.15 with a Total Asset Turnover recorded at a value of 0.07.AcelRx Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.50 and a Current Ratio set at 4.60.

Earnings per share (EPS) analysis for AcelRx Pharmaceuticals Inc. [ACRX] stock

With the latest financial reports released by the company, AcelRx Pharmaceuticals Inc. posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 42.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACRX.

AcelRx Pharmaceuticals Inc. [ACRX]: Insider Ownership positions

There are presently around $48 million, or 34.80% of ACRX stock, in the hands of institutional investors. The top three institutional holders of ACRX stocks are: BLACKROCK INC. with ownership of 7,614,345, which is approximately 34.983% of the company’s market cap and around 1.50% of the total institutional ownership; D. E. SHAW & CO., INC., holding 5,248,879 shares of the stock with an approximate value of $7.09 million in ACRX stocks shares; and VANGUARD GROUP INC, currently with $6.91 million in ACRX stock with ownership of nearly 28.687% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in AcelRx Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 48 institutional holders increased their position in AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] by around 12,582,617 shares. Additionally, 32 investors decreased positions by around 633,024 shares, while 14 investors held positions by with 22,519,341 shares. The mentioned changes placed institutional holdings at 35,734,982 shares, according to the latest SEC report filing. ACRX stock had 19 new institutional investments in for a total of 1,616,473 shares, while 15 institutional investors sold positions of 194,470 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam